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Abstract
Purpose A diet rich in berries is believed to play a dis-
tinct role in the prevention of metabolic diseases associated
with obesity. So far, there have been no published clinical
observations evaluating the influence of Aronia melano-
carpa on hemostasis. The aim of our study was to inves-
tigate the effects of A. melanocarpa extract (AM)
supplementation on platelet aggregation, clot formation,
and lysis in patients with metabolic syndrome (MS).
Methods Middle-aged non-medicated subjects with MS
(n = 38) and 14 healthy volunteers were included in this
study. Patients with MS were treated with 100 mg of AM
three times daily for 2 months.
Results We observed a significant reduction in the con-
centration of TC, LDL-C, and TG after AM supplementa-
tion. Beneficial changes in coagulation parameters were also
observed. After 1 month of AM administration, we noticed
significant inhibition of platelet aggregation. However, this
effect became less pronounced after 2 months of supple-
mentation. In the case of coagulation induced by endogenic
thrombin, a significant decrease in the overall potential for
coagulation was induced after 1 or 2 months of supple-
mentation. Moreover, after 1 month of AM extract supple-
mentation, we observed a beneficial reduction in the overall
potential for clot formation and fibrinolysis.
Conclusions We observed the normalization of hemos-
tasis parameters in MS patients after both 1 and 2 months
of AM administration. After 1 month of AM supplemen-
tation, we found favorable changes in regards to the overall
potential for plasma clotting, clot formation, and lysis, as
well as in the lipid profiles of subjects.
Keywords Aronia  Coagulation  Fibrinolysis 
Metabolic syndrome  Platelet aggregation
Introduction
A diet rich in berries is thought to play an important role in
the prevention of cardiovascular disease and cancer. It is
believed that a high dietary intake of berries, especially
Aronia melanocarpa (which is rich in polyphenols, such as
anthocyanins, procyanidins, and flavonoids), may inhibit
atherosclerotic plaque progression. Cyanidin glycosides are
believed to play a particularly important role in the pre-
vention of metabolic diseases associated with obesity.
There is evidence that cyanidin glycosides increase adipo-
nectin secretion in white fat tissue via AMP-dependent
kinase induction [1]. Anthocyanins also possess several
beneficial features. Similar to other polyphenols, they show
strong antioxidant effects, suppress inflammatory pro-
cesses, and prevent damage to the vascular endothelium [2].
Both in vitro and in vivo studies show promising results in
regards to the role of anthocyanins in preventing obesity
and ameliorating hyperglycemia and adipocyte function [3].
Anthocyanins also positively influence the circulatory sys-
tem by lowering blood pressure and by maintaining the
proper permeability and elasticity of arterial vessels [4, 5].
In metabolic syndrome, also known as syndrome X or
insulin resistance syndrome, the presence of dangerous risk
J. Sikora (&)  M. Markowicz  E. Mikiciuk-Olasik
Department of Pharmaceutical Chemistry and Drug Analyses,
Medical University of Lodz, Muszynskiego 1,
90-151 Lodz, Poland
e-mail: joanna.sikora@umed.lodz.pl
M. Broncel  M. Chałubin´ski  K. Wojdan
Department of Internal Diseases and Clinical Pharmacology,
Medical University of Lodz, Kniaziewicza 1/5,
91-347 Lodz, Poland
123
Eur J Nutr (2012) 51:549–556
DOI 10.1007/s00394-011-0238-8
factors for cardiovascular disease (including abdominal
obesity, lipid disorders, and atherogenic dyslipidemia) is
combined with impaired glucose tolerance and elevated
blood pressure. Patients with MS have a threefold greater
risk of acute coronary syndrome, a twofold greater risk of
death, and a fivefold greater risk of developing type 2
diabetes. Enhanced serum levels of pro-inflammatory
cytokines (IL-6 and TNF-a) and C-reactive protein (CRP)
have been observed in patients with metabolic syndrome,
along with microalbuminuria and an increase in coagula-
bility [2, 6]. Several studies have shown that obese patients
(when compared to non-obese controls) have higher plasma
concentrations of all pro-thrombotic factors (fibrinogen,
von Willebrand factor—vWF, and factor VII), as well as
higher plasma levels of plasminogen activator inhibitor-1
(PAI-1) [7]. A positive association has been found to exist
between central obesity and the changes mentioned above.
It has been proposed that the secretion of IL-6 by adipose
tissue, combined with the actions of adipose tissue
expressed TNF-alfa in obese individuals, might be the basis
for the association between insulin resistance, endothelial
dysfunction, coagulopathy, and coronary heart disease.
Finally, some hormonal abnormalities (pertaining to
androgens and catecholamines) associated with the accu-
mulation of body fat may contribute to the impairment of
the coagulative pathway in obesity [6, 7].
The aim of our study was to investigate the effects of
A. melanocarpa extract supplementation on platelet aggre-




We used adenosine 50-diphosphate (ADP) produced by
Sigma-Aldrich (Munich, Germany), thrombin produced by
Biomed (Lublin, Poland), and recombinant tissue plas-
minogen activator (t-PA) produced by Boehringer (Ingel-
heim, Germany). Tris-buffered saline (TBS) and calcium
chloride were obtained from Polish Chemical Reagents
(Gliwice, Poland). A. melanocarpa extract (AM) was pur-
chased from Agropharm SA (Poland).
Subjects
The study included 52 subjects (42–65 years old) subdi-
vided into two groups. The study group (n = 38; 22 women
and 16 men) included patients with metabolic syndrome.
The control group consisted of 14 healthy volunteers (9
women and 5 men) matched for age and sex. Patients were
eligible for the study if they met the following criteria:
(1) waist circumference C80 cm for women and C94 cm
for men, (2) TG level [150 mg/dL (1.7 mmol/L), (3) HDL-
C level \40 mg/dL (1.0 mmol/L) for men and \50 mg/dL
(1.3 mmol/L) for women. The exclusion criteria consisted
of (1) secondary dyslipidemia in the course of autoimmune
disorders, thyroid disease, chronic pancreatitis, nephritic
syndrome, liver or biliary tract disease, or alcoholism, (2)
any acute or chronic inflammatory processes, (3) congestive
heart failure, (4) coronary artery disease, (5) history of
myocardial infarction, stroke, or intermittent claudication,
(6) moderate or severe arterial hypertension (WHO/ISH
grade 2 or 3), (7) diabetes mellitus, (8) impaired renal or
hepatic function, (9) malabsorption syndromes, (10)
malignancy or history of malignancy, (11) treatment with
hypolipemic, hypotensive, anticoagulant, antiplatelet, or
profibrinolytic drugs, (12) concomitant treatment with drugs
that may affect inflammatory processes in the vascular wall,
including non-steroidal anti-inflammatory drugs, and
angiotensin-converting enzyme inhibitors, (13) antioxidant
therapy, (14) ongoing hormonal replacement therapy or oral
contraception, (15) abuse of alcohol, (16) cigarette smoking,
and (17) poor patient compliance.
Ethics
All subjects gave their written informed consent prior to
participating in the study. The study was approved by the
Bioethics Commission of the Medical University of Lodz
(No. 241/06/KB).
Study design
Subjects with MS were treated with 100 mg of A. mela-
nocarpa extract three times daily during the 2-month
study period. This extract contained ca. 60 mg of total
polyphenols, including a minimum of 20 mg of anthocy-
anins: 3-O-cyanidin-galactoside (64.5%), 3-O-cyanidin-
arabinoside (28.9%), 3-O-cyanidin-xyloside (4.2%), and
3-O-cyanidinglucoside (2.4%). All participants of this
study were on the low-fat diet (started 3 months before
initiating active treatment with A. melanocarpa extract and
continued till the end of the experiment). 30% of an indi-
vidual’s daily calories originated from fat, including no
more than 10% of calories from saturated fat. Participants
were instructed not to modify their usual food intake and
physical activity during the study. Additionally, ingestion
of products containing black chokeberry (juices, jams,
fresh, or frozen fruits) was prohibited. Three control visits
were scheduled for the subjects: before initiation of treat-
ment, after 1 month of therapy, and after 2 months of
therapy. During the control visits, subjects underwent
clinical examination, measurement of body weight and
waist circumference, urine analysis, and venous blood
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sampling in order to evaluate the studied parameters and
the safety of laboratory parameters. The following
parameters were analyzed in blood samples: total and dif-
ferential blood cell count, blood sedimentation rate, alanine
and aspartate aminotransferases, electrolytes, bilirubin,
creatinine, and total proteins. Blood samples were taken
after an overnight fast in a quiet, temperature-controlled
room (24–25 C) between 8:00 and 9:00 a.m., in order to
avoid circadian fluctuations. The samples were immediately
coded so that the person performing the laboratory assay
was unaware of the subject’s identity and study sequence.
Compliance was assessed during each visit by tablet counts
and was considered satisfactory when the number of tablets
taken by the patient ranged from 90 to 100%.
Sample preparation
Blood was collected into Vacuette Coagulation Tubes
(Greiner Bio-One, Austria) containing 3.2% buffered
sodium citrate. Platelet-rich plasma (PRP) was obtained by
blood centrifugation (at 1509g, for 10 min, at room tem-
perature). Platelet-poor plasma (PPP) was obtained by
subsequent centrifugation of the PRP (2,5009g, 20 min,
4 C). PPP was stored at -70 C until the measurements
were taken. The platelet count in the PRP was adjusted to
1.8 9 108 platelets/mL. To preserve the discoid shape of
platelets, the PRP was restored in a water bath at 37 C
during a resting period of 30 min.
Platelet aggregation assay
The aggregation of platelets in the PRP was measured with
Born’s turbidimetric method [8] using a spectrophotometer
(Cecil CE2021, London, England) at 37 C and with stir-
ring. Aggregation curves were induced by the addition of
ADP (10 lmol/L) and were recorded and evaluated by our
own computer program [9]. Our program estimated 5
parameters of platelet aggregation: maximal aggregation
(Amax), initial velocity (v0), the time needed to reach
maximal aggregation (Tmax), the aggregation level after
5 min (A5min) from Amax (which enabled us to estimate
disaggregation), and platelet shape change (PSC, which is
only a rough estimation of this process).
Test of clot formation and lysis (CL-test)
For this study, we used the CL-test (previously described by
us), in conjunction with our own computer program [10].
This test is based on the evaluation of the global assay of
coagulation and fibrinolysis by measuring changes in optical
transmittance. To obtain a clotting and lysis curve, thrombin
(final concentration 0.5 IU/mL) and t-PA (final concentra-
tion, 60 ng/mL) were added to three-time diluted PPP with
TBS buffer. The addition of small amounts of thrombin
(0.025 IU/mL) and calcium chloride (0.01 mmol/mL) does
not result in coagulation initiation, but rather induces a
feedback reaction that leads to endogenous thrombin gen-
eration, and as such, to clot formation. Curves were recorded
continuously using a spectrophotometer (Cecil CE2021,
London, England) at 37 C and with stirring. They were then
evaluated by the computer program. The following kinetic
parameters of the examined processes were calculated:
CAUC—overall potential of coagulation, TGt—thrombin
generation time, CLAUC—overall potential of clot formation
and lysis—phase I (clot formation): Tt—thrombin time,
Fmax—maximum clotting, Tf—plasma clotting time, Fvo—
initial plasma clotting velocity, Sf—area under the clot for-
mation curve; phase II (forming a stable): Tc—clot stabil-
ization time, Sc—area under the curve of stable clot
formation; and phase III (fibrinolysis): Lmax—maximum
lysis, Tl—fibrinolysis time, Lvo—initial clot fibrinolysis
velocity, Sl—area under the fibrinolysis curve.
Other laboratory assays
The other laboratory parameters were determined with
routinely used methods at the Dr. W. Bieganski Voivodship
Specialistic Hospital in Lodz. Lipid profile: total serum
cholesterol (TC), triglycerides (TG), and high-density
lipoprotein cholesterol (HDL-C) were determined by
means of enzymatic methods (Olympus AU 400 analyzer;
reagent kits produced by bioMerieux). Low-density lipo-
protein cholesterol (LDL-C) was calculated using Friede-
wald’s formula [11]. Fibrinogen levels were measured
according to the Clauss method [12] with the use of
reagents supplied by FibriquikTM and the Coag-A-Mate
MTX analyzer (bioMerieux).
Statistics
All values are expressed as means ± SD. Statistical tests
were performed using a commercial software package
(Statistica 8.0, StatSoft). The Kolmogorov–Smirnov test
was applied to determine whether the continuous variables
were normally distributed. For with-in-group comparison,
variables showing normal distributions were evaluated
using the paired t test, while variables showing non-normal
distributions were evaluated using the Wilcoxon signed
rank test. A p value of less than 0.05 was considered sta-
tistically significant.
Results
The main baseline characteristics of subjects with meta-
bolic syndrome (MS) are shown in Table 1, along with the
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characteristics of the control group. The effects of
A. melanocarpa extract supplementation after one (1 m)
and 2 months (2 m) of therapy are also presented in
regards to plasma lipid levels, body mass index (BMI), and
waist circumference. No significant adverse effects were
recorded, and all patients completed the study. All labo-
ratory safety measurements remained within normal limits.
The mean values of total cholesterol (TC), LDL-C, TG,
BMI, and waist circumference were significantly higher in
subjects with MS than in the control group p \ 0.001.
HDL-C was significantly lower in subjects with MS when
compared with the control group. Supplementation with
AM extract for one or 2 months resulted in significant
decreases in TC, LDL-C, and TG; however, these values
were still markedly higher in subjects with MS when
compared with the control group (p \ 0.001). During the
study period, no changes in HDL-C, BMI, and waist cir-
cumference were observed in subjects with MS.
Table 2 compares the average values of aggregation
kinetic parameters and the number of platelets in patients
suffering from metabolic syndrome as well as in the control
group. There were no statistically essential differences
between these groups. After 1 month of supplementation
with AM extract, we observed a statistically significant
inhibition of platelet aggregation. The inhibition of platelet
aggregation was manifested by a reduction in maximal
aggregation (Amax), a diminished initial velocity of the
process (vo), and an increase in the time after which Amax
was reached. However, after 2 months of supplementation,
the average values of the aggregation parameters were
comparable with those from before supplementation.
We observed no statistically significant differences
between the groups (after 1 and 2 months of supplemen-
tation) in regards to alterations in shape (PSCmax) and in
regards to the number of platelets (PLT).
The kinetic parameter values for the processes of clot
formation and fibrinolysis, as well as for coagulation itself,
are presented in Tables 3 and 4, respectively. In patients
with MS, the overall potential for clot formation and lysis
(CLAUC), as well as coagulation (CAUC), were both initially
elevated in comparison with the control group. Further-
more, in regards to the evaluation of CLAUC, the time of
coagulation (Tf) was lengthened and the initial velocity
(Fvo) of plasma coagulation was decreased under the
influence of exogenous thrombin and the duration of the
transitional phase (Tc). However, the time of coagulation
induced by endogenic thrombin was shortened (Tf).
After 1 month of AM supplementation, we observed a
statistically significant decrease in the overall potential for
clot formation and fibrinolysis (CLAUC), as well as in all of
the constituents under the curve of this process (Sf, Sc, and
Sl). Furthermore, we estimated that the maximum of
coagulation (Fmax) and fibrinolysis (Lmax) was also both
reduced. Moreover, the times of these processes (Tf and Tl)
changed in a statistically significant manner. After
2 months, we did not observe any statistically significant
differences between the determined kinetic parameters of
clot formation and fibrinolysis.
In regards to coagulation induced by endogenic throm-
bin, both 1 and 2 months of supplementation induced a
statistically significant decrease in the overall potential of
coagulation (CAUC), reaching values normally found
among healthy individuals.
Throughout the study period, the concentration of
fibrinogen among patients with MS was statistically higher
than among healthy individuals. One month of AM extract
supplementation did not influence the concentration of
fibrinogen. However, after 2 months of supplementation,
we observed a statistically significant increase in fibrinogen
concentration when compared to initial values.
Discussion
Aronia and other berries have been extensively investi-
gated since it was discovered that natural polyphenols,
Table 1 Characteristics of the control group and patients with metabolic syndrome (mean ± SD) at baseline, after 1 and 2 months of
A. melanocarpa extract therapy
Parameter Patients with metabolic syndrome Control group
Baseline 1 month 2 months
TC (mg/dL) 244.2 ± 35.1 228.3 ± 34.4?? 228.5 ± 35.2?? 190.7 ± 27.4
LDL (mg/dL) 158.3 ± 33.4 150.7 ± 31.8? 144.8 ± 30.1?? 115.9 ± 16.1
HDL (mg/dL) 42.8 ± 4.8 44.5 ± 5.4 44.1 ± 12.1 57.2 ± 9.2
TG (mg/dL) 187.1 ± 83.4 160.3 ± 94.4? 170.5 ± 98.9? 90.1 ± 30.5
BMI (kg/m2) 31.1 ± 3.3 30.8 ± 3.2 30.9 ± 3.2 24.4 ± 1.5
Waist circumference (cm) 97.0 ± 9.0 96.4 ± 8.8 96.7 ± 8.5 84.2 ± 9.8
TC total cholesterol, LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, TG triglyceride
? p = 0.05; ?? p \ 0.05 versus baseline
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Table 2 ADP-induced platelet aggregation kinetic parameters (mean ± SD) of the control group and patients with metabolic syndrome at
baseline and after 1 and 2 months of A. melanocarpa extract therapy
ADP-induced platelet aggregation Patients with metabolic syndrome Control group
Baseline 1 month 2 months
Amax (%T) 27.3 ± 13.0 19.6 ± 10.0
??? 26.2 ± 12.9 23.9 ± 15.5
v0 (%T/min) 18.4 ± 13.3 11.8 ± 8.6
?? 16.0 ± 13.2 16.9 ± 12.8
Tmax (s) 376.4 ± 174.3 444.5 ± 168.4
?? 379.1 ± 172.7 347.1 ± 165.3
PSCmax (%T) 4.2 ± 2.4 4.4 ± 1.5 3.6 ± 2.7 4.2 ± 1.7
PLT (9109/L) 283.2 ± 72.7 277.3 ± 63.7 277.1 ± 58.0 244.8 ± 63.8
Amax maximal aggregation, v0 initial velocity, Tmax time needed to reach Amax, PSCmax maximal platelet shape change, PLT platelet count
??? p \ 0.001; ?? p \ 0.05 versus baseline
Table 3 Overall potential for clot formation and lysis kinetic parameters (mean ± SD) of the control group and patients with metabolic
syndrome at baseline and after 1 and 2 months of A. melanocarpa extract therapy
Phase Parameter Patients with metabolic syndrome Control group
Baseline 1 month 2 months
I Tt (s) 34.8 ± 5.7 39.81 ± 19.8 38.0 ± 8.9 35.6 ± 3.5
Fmax (%T) 46.9 ± 8.7 40.0 ± 12.1
??? 43.2 ± 11.3 47.7 ± 13.0
Tf (s) 103.1 ± 27.2* 94.0 ± 22.0?? 97.1 ± 28.4 90.5 ± 25.9
Fvo (%T/min) 68.0 ± 24.1** 69.8 ± 32.7** 72.8 ± 29.5* 99.2 ± 40.7
Sf (%T 9 min) 55.0 ± 19.8 42.7 ± 14.8
?? 48.5 ± 22.7 50.9 ± 17.0
II Tc (s) 431.7 ± 82.4** 426.9 ± 125.0** 443.7 ± 86.9** 364.0 ± 66.7
Sc (%T 9 min) 329.9 ± 93.7 289.0 ± 115.6
?? 307.2 ± 95.7 278.8 ± 79.6
III Lmax (%T) 43.4 ± 11.2 38.14 ± 14.0
?? 41.9 ± 11.7 44.5 ± 10.9
Tl (s) 268.2 ± 61.4 283.7 ± 62.6?? 289 ± 54.4 241.9 ± 57.7
Lvo (%T/min) 14.5 ± 6.5 12.0 ± 6.4 13.8 ± 7.3 19.3 ± 16.2
Sl (%T 9 min) 135.4 ± 54.5 110.1 ± 48.4
??? 114.4 ± 36.1 116.6 ± 35.8
CLAUC (%T 9 min) 518.6 ± 155.2* 442.1 ± 170.7
?? 470.6 ± 146.5 446.3 ± 123.4
Fb (mg/dL) 290.9 ± 78.2*** 281.9 ± 70.9** 322.5 ± 68.0???/** 214.7 ± 36.7
Phase I (clot formation): Tt thrombin time, Fmax maximum clotting, Tf plasma clotting time, Fvo initial plasma clotting velocity, Sr area under the
clot formation curve; Phase II (forming a stable): Tc clot stabilization time, Sc area under the curve of a stable clot formation; Phase III
(fibrinolysis): Lmax maximum lysis, Tl fibrinolysis time, Lvo initial clot fibrinolysis velocity, Sf area under the fibrinolysis curve; CLAUC overall
potential for clot formation and lysis, Fb fibrinogen
*** p \ 0.001; ** p \ 0.05; * p = 0.05 versus control group; ? p = 0.05; ?? p \ 0.05 versus baseline
Table 4 Overall potential of plasma clotting kinetic parameters (mean ± SD) of the control group and patients with metabolic syndrome at
baseline and after 1 and 2 months of A. melanocarpa extract therapy
Parameter Patients with metabolic syndrome Control group
Baseline 1 month 2 months
TGt (s) 140.7 ± 38.4 143.3 ± 48.89 183.2 ± 55.0?? 151.0 ± 47.7
Fmax (%T) 70.8 ± 9.9 63.5 ± 14.28
?? 66.4 ± 14.1 63.2 ± 14.5
Tf (s) 59.5 ± 18.0** 68.9 ± 44.42 68.7 ± 17.9 75.9 ± 26.4
Fvo (%T/min) 135.4 ± 48.5 121.9 ± 47.62 112.9 ± 32.8 113.6 ± 60.6
CAUC (%T 9 min) 1,182.4 ± 168.9* 1,066.8 ± 246.14
?? 1,071.4 ± 233.5?? 1,006.5 ± 290.4
TGt thrombin generation time, Fmax maximum clotting, Tf plasma clotting time, Fvo initial plasma clotting velocity, CAUC overall potential for
clotting
* p = 0.05; ** p \ 0.05 versus control group; ?? p \ 0.05 versus baseline
Eur J Nutr (2012) 51:549–556 553
123
including anthocyanins from various berries, exhibit sev-
eral health-promoting properties [13].
The cardioprotective activity of AM and AM extracts
can be attributed to the effects of anthocyanins. Anthocy-
anins are lipid-lowering, anti-aggregative, and also exert
direct vasoactive action. It should also be mentioned that
AM fruits contain significant amounts of niacin, well rec-
ognized for its lipid-lowering activity [5]. The lipid-low-
ering activity of AM preparations has been documented
with the use of rat models with artificially induced hyper-
cholesterolemia [14]. It has also been observed that regu-
larly drinking ([6 weeks) AM juice has a beneficial effect
on lipid concentrations. Furthermore, a significant decrease
in TC, LDL-C, and TG was observed in patients with mild
hypercholesterolemia who were not undergoing pharma-
cological treatment (along with an increase in HDL2) [15].
In a double-blind placebo-controlled parallel trial, AM
extract was administered in combination with statins to
patients after myocardial infarction. Regardless of the
statins, the polyphenol-rich extract significantly reduced
the LDL-C oxidation status, blood pressure, and inflam-
matory marker levels (8-isoprostans, hs-CRP, MCP-1)
[16].
During our previous studies on the influence of AM
extract, we observed the advantageous decrease in blood
pressure, lipid and endothelin-1 concentrations, and levels
of oxidative stress markers in 25 patients suffering from
MS [17].
Recent experiments have confirmed these aforemen-
tioned observations. After supplementation with AM
extract for 1 and/or 2 months, we observed statistically
significant reductions in the concentrations of TC, LDL-C,
and TG among 38 patients with MS. However, during the
time of supplementation, alterations in levels of HDL-C
were not confirmed.
The anti-platelet activity of polyphenolic AM fruit
extract has been confirmed by numerous in vitro studies
[18–20]. It should also be noted that the results obtained
from in vitro tests significantly differ from those of in vivo
studies, as aronia anthocyanins are sensitive to alkaline
pancreatic digestion, which substantially modulates their
bioavailability [5]. So far, no clinical observations evalu-
ating the influence of aronia on platelet activity and the
overall potential for coagulation and lysis have been pub-
lished. However, there are published studies confirming the
beneficial activity of other berries (rich in polyphenols) on
platelet function. A preliminary investigation by Wilson
et al. [21] evaluated the ability of cranberry juice to inhibit
platelet aggregation in vivo. After 4 days of consuming
cranberry juice four times a day, ADP- and collagen-
induced platelet aggregation declined significantly com-
pared to baseline values. These aggregation responses
returned to near baseline levels 4 days after cessation of
cranberry juice consumption. Attempts to recreate the
inhibition of platelet aggregation in vitro by adding cran-
berry juice to platelet-rich plasma from subjects who did
not consume cranberry juice were not successful [22]. The
favorable effects of berry consumption on platelet function
were confirmed by a single-blind, randomized, placebo-
controlled intervention trial. Seventy-two volunteers con-
sumed 2 portions of berries daily for 8 weeks. Berry con-
sumption significantly inhibited platelet function, measured
with a PFA-100 analyzer using a membrane coated with
ADP and collagen (CADP-CT). The occlusion time in the
CADP-CT system was prolonged by 11% in the berry
consuming group. The intervention had no significant
effects when epinephrine and collagen were used as
platelet activators. Likewise, other plasma biomarkers of
platelet activation, coagulation, and fibrinolysis did not
change during the intervention [23].
Our studies showed that 1 month of AM extract sup-
plementation significantly inhibited ADP-induced platelet
aggregation. We observed not only a 30% decrease in
aggregation (Amax), but also slowing of this process by over
35%, resulting in the lengthening of the time required to
reach the aggregation maximum by about 20%. This
observed effect may have some positive implications for
the prevention of coronary incidents related to platelet
hyperactivity frequently observed among patients with MS
[4]. After 2 months of treatment with AM extract, average
values of kinetic parameters of aggregation were only
slightly lower than initial values. Compliance with the
study protocol appeared to be proper after 1 and 2 months
of supplementation. Supplementation with AM extract did
not influence the general number of platelets in the blood of
the examined patients. Furthermore, in every patient, the
number of platelets in the PRP used for the estimation of
aggregation was always (baseline, 1 and 2 m) brought by
PPP to the same value. This is of vital importance because
the measured kinetic parameters of aggregation closely
depend on the number of platelets in the PRP.
The multi-parameter test utilized in this study of coag-
ulation and fibrinolysis was developed for the in vitro
screening of drugs [10]. The usefulness of this method in
regards to ex vivo studies was confirmed by a study on a
group of 298 elderly subjects. In this group, correlations
were observed between the measured kinetic parameters
and some of the other typical methods of hemostasis
evaluation, as well as between factors such as sex, age,
smoking, alcohol consumption, obesity, and physical
activity [24]. Antovic [25], by means of spectrophotomet-
ric measurement of the overall potential for coagulation
(OHP) and fibrinolysis (OFP), showed the existence of
correlations between these parameters and different con-
centrations of coagulation factors (II, V, VII, VIII, IX, X,
XI) during in vitro tests. The OHP assay was also evaluated
554 Eur J Nutr (2012) 51:549–556
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in connection with hypercoagulation in normal pregnancy,
preeclampsia, some thrombophilias, coronary heart dis-
ease, diabetes, stroke, and vascular surgery, as well as with
hypocoagulability. The possible usefulness of the assay in
monitoring anticoagulant treatment was also revealed [25].
In our studies, we observed statistically higher initial
values for the overall potential of clot formation and lysis
(CLAUC), overall potential for plasma clotting (CAUC), and
concentrations of fibrinogen in patients with MS when
compared with the control group. We also observed some
interesting differences between the individual kinetic
parameters of CLAUC when comparing patients with MS
and the control group. In the control group, we observed a
statistically faster formation of fibrinogen fibers under the
influence of exogenous thrombin (higher value of Fvo and
shortened Tf), and a considerably faster beginning to the
lysis of the formed clot (shortened Tc value). Despite
the fact that we did not observe significant changes in the
kinetics of fibrinolysis, we observed that this examined
process functions more efficiently in healthy patients.
Alterations of this kind might point to an increase in the
thrombotic risk of patients with MS.
After 1 month of supplementation with AM extract, we
observed a beneficial reduction in the overall potential for
clot formation and fibrinolysis (CLAUC). This change was
observed for the area under the curve of all three phases of
the examined process (Sf, Sc, and Sl). This observation
may indicate that AM supplementation resulted in the
modification of many hemostasis factors. However, further
molecular studies are required to determine whether these
effects are the result of the direct influence of AM on the
activity of hemostasis factors or whether these pleiotropic
effects are the result of the in vivo activity of AM
compounds (anti-inflammatory, influencing function of
endothelium, anti-aggregatory, and hypolipemic). After
2 months of AM supplementation, the direction of CLAUC,
Sf, Sc, and Sl change was still the same and the measured
parameters were still 11% lower on average than initial
values. However, these differences were not statistically
significant. In the case of the overall potential for coagu-
lation (CAUC), a comparable and beneficial influence was
observed after 1 and 2 months of AM extract administra-
tion. Although kinetic parameters of the first phase of CL-
test and the parameters describing the overall potential of
coagulation seem the same, it should be noticed that in fact
they differ from each other.
Since fibrin formation is induced by high concentrations
of exogenous thrombin in the CL-test, the observed alter-
ation to the parameters (e.g., Fmax, Tf) results from changes
to the fibrinogen particle that influences the structure of the
formed clot. It has been confirmed in literature that modifi-
cation of fibrinogen particles and fibrin (for example as a
result of glycation) causes the formation of a fibrin net with
an abnormal structure [26]. In the evaluation of the overall
potential of coagulation, the addition of small amounts of
thrombin with calcium chloride does not result in coagula-
tion initiation but rather induces a feedback reaction leading
to the generation of endogenous thrombin, resulting in clot
formation. By using both of these tests, a more accurate
screening test for the generation of endogenic thrombin as
well as clot formation and lysis can be obtained.
The current study has some limitations. The small
number of subjects and the design of the study (a placebo-
treated group was not included) are both limiting factors;
however, this study may be treated as a pilot study.
In conclusion, normalization of hemostasis parameters
was observed in patients with metabolic syndrome after
both 1 and 2 moths of AM extract administration. We
found favorable changes in the overall potential of plasma
clotting (CAUC), clot formation and lysis (CLAUC), and the
lipid profile of subjects after the consumption of A. mela-
nocarpa extract for 1 month. The beneficial effect of
supplementation with AM extract was weaker in regards to
platelet aggregation.
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